At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 25 enrolled
Drug / intervention
OBI-833/OBI-821drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Study to Assess the Safety, Tolerability, and Efficacy of Active Immunotherapy With Dose Escalation and Cohort Expansion of OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal, or Breast Cancer Subjects
In Brief
A Phase 1 clinical trial evaluating OBI-833/OBI-821 for Metastatic Gastric Cancer and 3 related conditions. Completed, enrolled 25 participants across 4 sites.
Detailed Summary
The purpose of this clinical study is to assess the safety and tolerability and efficacy of active immunotherapy with dose escalation and cohort expansion of OBI-833 in advanced/metastatic gastric, lung, colorectal, or breast cancer subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Gastric Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Lung Cancer
CountriesTaiwan
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartDec 2015
Primary CompletionDec 2020
Study CompletionFeb 2021
TodayJul 2026
First PostedDec 8, 2014
Enrollment StartDec 22, 2015
Primary CompletionDec 22, 2020
Study CompletionFeb 2, 2021
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 11.6 years ago
Interventions
OBI-833/OBI-821drug